GHZ339

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Atopic DermatitisModerate to severe atopic dermatitis

Phase 2

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

RecruitingNCT06947993

Novartis PharmaceuticalsAtopic Dermatitis

Start: 2025-05-16End: 2028-12-22Target: 224Updated: 2026-08-19

A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis

RecruitingCTIS2024-519081-49-00

Novartis Pharma AGModerate to severe atopic dermatitis

Start: 2025-10-28Target: 104Updated: 2025-12-19